Back to Search
Start Over
Research Paper: Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
- Source :
-
Basic & Clinical Neuroscience . Jul/Aug2020, Vol. 11 Issue 4, p491-498. 8p. - Publication Year :
- 2020
-
Abstract
- Introduction: Primary Diffuse Large B Cell Lymphoma of CNS (PCNSL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL) and presents with an aggressive clinical course and usually resistant to commonly used therapy regimens. Recently, role of immune checkpoint molecules including PD-1 and PD-L1 confirmed in some solid tumors and lymphoma resulting tumor cells escape the immune system and help to survive and to spread. Inhibitors of PD-1 and PD-L1 have shown lasting responses in several solid and some hematological tumors, while limited studies evaluate checkpoint molecules on PCNSL. Method: In this study, we investigated PD-1 and PD-L1 expression by immunostaining on 71 patients with PCNSL and correlation with demographic data, location of the tumor, proliferation rate, cell of origin, and CD8 positive T cell infiltration in tumor microenvironment. Results: 16 from71 showed PD-1 expression, while PD-L1 expression were 42/71. No association was determined between PD-1/PD-L1 expression and gender, cell of origin, and proliferation rate, but a highly significant difference was determined between the infiltration of CD8 positive T cells in two groups of PD-1/PD-L1 positive and negative. Conclusion: This study revealed expression of check point molecules in remarkable number of PCNSL which may open new therapeutic recommendations in this aggressive lymphoma type. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2008126X
- Volume :
- 11
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Basic & Clinical Neuroscience
- Publication Type :
- Academic Journal
- Accession number :
- 146779680
- Full Text :
- https://doi.org/10.32598/bcn.11.4.2542.1